Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 22.06M -62.1% |
| Revenue (ttm) | 1.29M -39.9% |
| Net Income | -31.33M |
| EPS | -19.03 |
| Shares Out | 4.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,338 |
| Average Volume | 41,060 |
| Open | 514.80 |
| Previous Close | 514.80 |
| Day's Range | 500.00 - 523.90 |
| 52-Week Range | 433.10 - 4,200.00 |
| Beta | 0.03 |
| RSI | 51.21 |
| Earnings Date | Aug 26, 2026 |
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat... [Read more]
Financial Performance
In 2025, Can-Fite BioPharma's revenue was $405,000, a decrease of -39.91% compared to the previous year's $674,000. Losses were -$9.83 million, 24.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
D. Boral Capital upgraded Can-Fite BioPharma (CANF) to Buy from Hold with a $7 price target The firm, which notes that its prior downgrade was driven primarily by the reverse…
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies Ramat Gan, Israel, May 13, 2026 (GLOBE ...
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth adjusted the firm’s price target on Can-Fite BioPharma (CANF) to $5 from $2.50 and keeps a Buy rating on the shares. The firm cites the…
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small mole...
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
Represented by 1,647,449 American Depositary Shares. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRank...
Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs
Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs
Can-Fite BioPharma completes enrollment in Piclidenoson study
Can-Fite BioPharma (CANF) announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs. Vetbiolix, Can-Fite’s...
Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biot...
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targ...
Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment
Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
Can-Fite BioPharma (CANF) announced that the Israeli Patent Office has allowed its patent application No. 284463, titled “An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect.”
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE Americ...
Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants
(RTTNews) - Can-Fite BioPharma Ltd. (CANF) announced that its investigational drug Namodenoson successfully met the primary endpoint in a Phase 2a study for advanced pancreatic ductal adenocarcinoma (...
Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study
Can-Fite BioPharma Ltd. (AMEX: CANF) shares are up on Wednesday following the company's announcement that its drug, Namodenoson, successfully met the primary endpoint in a Phase 2a study for pretreate...
Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study
Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
Can-Fite BioPharma (CANF) announced results from its Phase IIa open-label study evaluating namodenoson in patients with advanced pancreatic ductal adenocarcinoma who had progressed following prior sys...
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small mole...
Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results
Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
Can-Fite BioPharma (CANF) announced the publication of a peer-reviewed study in the International Journal of Obesity demonstrating the anti-obesity effect of namodenoson, the Company’s lead drug candi...
Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson
Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
Can-Fite BioPharma (CANF) announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002, titled “An A3 adenosine receptor ligand for use for
Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant
Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
Can-Fite BioPharma (CANF) announced that a patient with advanced decompensated liver cirrhosis who was treated with Namodenoson subsequently underwent a successful liver transplantation. The patient r...
Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial
Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
Can-Fite BioPharma (CANF) announced that patient enrollment has been completed in its Phase 2a pancreatic cancer clinical trial of Namodenoson. The study is evaluating the safety, clinical activity, a...